image credit: Unsplash

FDA delays verdict for Biogen’s closely watched Alzheimer’s drug, raising investor optimism

Aducanumab has taken one of the most winding paths of any drug in recent history.

After going through initial clinical testing, Biogen pushed two doses of the drug into a pair of large, identically-designed studies meant to prove its merit in early Alzheimer’s patients. The studies, named ENGAGE and EMERGE, started a month apart in the late summer of 2015. Biogen amended the studies a few times over the following few years, but the first major, course-changing event for aducanumab didn’t come until March 2019.

Read More on Biopharma Dive